PT  - JOURNAL ARTICLE
AU  - Jia, Long
AU  - Zhang, Qi
AU  - Zhang, Rongxin
TI  - PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
AID  - 10.20892/j.issn.2095-3941.2017.0086
DP  - 2018 May 01
TA  - Cancer Biology and Medicine
PG  - 116--123
VI  - 15
IP  - 2
4099  - http://www.cancerbiomed.org/content/15/2/116.short
4100  - http://www.cancerbiomed.org/content/15/2/116.full
SO  - Cancer Biol Med2018 May 01; 15
AB  - Cancer immunotherapy has greatly advanced in recent years, and PD-1/PD-L1 blocking therapy has become a major pillar of immunotherapy. Successful clinical trials of PD-1/PD-L1 blocking therapies in cancer treatments have benefited many patients, which promoted the Food and Drug Administration (FDA) approval of PD-1/PD-L1 blocking drugs. In this review, we provide a detailed introduction of five PD-1/PD-L1 blocking drugs, with indications and studies, as a valuable reference for doctors and medical investigators. Moreover, the characteristics of PD-1/PD-L1 blocking therapies, including their universality and sustainability, are discussed in this review. Furthermore, we also discuss and predict the possibility of PD-L1 as an indication marker of PD-1/PD-L1 blocking therapy for pan-cancer treatment, and the current status of combination therapies.